Replies to post #512544 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Another way of looking at this is that the comparison between control arm and treatment arm may have effectively/pragmatically stopped at around 297 or 298 patients.

[meirluc]

[quoteMaybe we need to wait and see what the data really shows us. If, we assume that 34 sicker patients on average entered the treatment group after the control decided not to enroll its final 17, then you might see more clearly what the parties were dealing with.][/quote]

I agree with the first sentence that we have to wait and see the complete data and I am especially curious as to how the crossovers fared from the 36 month timeline and beyond. however, if we assume that that 34 sicker patients on average entered the treatment group after the control decided not to enroll its final 17, why did the last 108 patients when compared to the initial 223 patients, demonstrate such an impressive survival capacity?

Hopefully such questions will be answered by the imminent or soon to come publication.